• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Large owner Gv 2019 Gp, L.L.C. disposed of 147,552 shares and sold $3,459,809 worth of shares (147,552 units at $23.45) (SEC Form 4)

    5/18/26 6:43:00 PM ET
    $LIFE
    Specialty Insurers
    Finance
    Get the next $LIFE alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    GV 2019 GP, L.L.C.

    (Last)(First)(Middle)
    1600 AMPHITHEATRE PARKWAY

    (Street)
    MOUNTAIN VIEW CALIFORNIA 94043

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Ethos Technologies Inc. [ LIFE ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    05/14/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    XForm filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Class A Common Stock05/14/2026J(1)60,077D$03,138,172IBy GV 2019, L.P.(2)
    Class A Common Stock05/14/2026S60,077D$23.0093(3)0IBy Alphabet Holdings LLC(4)
    Class A Common Stock05/15/2026J(1)87,475D$03,050,697IBy GV 2019, L.P.(2)
    Class A Common Stock05/15/2026S45,410D$23.2691(5)42,065IBy Alphabet Holdings LLC(4)
    Class A Common Stock05/15/2026S42,065D$24.2679(6)0IBy Alphabet Holdings LLC(4)
    Class A Common Stock571,907IBy GV 2021, L.P.(7)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    1. Name and Address of Reporting Person*
    GV 2019 GP, L.L.C.

    (Last)(First)(Middle)
    1600 AMPHITHEATRE PARKWAY

    (Street)
    MOUNTAIN VIEW CALIFORNIA 94043

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    1. Name and Address of Reporting Person*
    GV 2019 GP, L.P.

    (Last)(First)(Middle)
    1600 AMPHITHEATRE PARKWAY

    (Street)
    MOUNTAIN VIEW CALIFORNIA 94043

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    1. Name and Address of Reporting Person*
    GV 2019, L.P.

    (Last)(First)(Middle)
    1600 AMPHITHEATRE PARKWAY

    (Street)
    MOUNTAIN VIEW CALIFORNIA 94043

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    1. Name and Address of Reporting Person*
    GV 2021 GP, L.L.C.

    (Last)(First)(Middle)
    1600 AMPHITHEATRE PARKWAY

    (Street)
    MOUNTAIN VIEW CALIFORNIA 94043

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    1. Name and Address of Reporting Person*
    GV 2021 GP, L.P.

    (Last)(First)(Middle)
    1600 AMPHITHEATRE PARKWAY

    (Street)
    MOUNTAIN VIEW CALIFORNIA 94043

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    1. Name and Address of Reporting Person*
    GV 2021, L.P.

    (Last)(First)(Middle)
    1600 AMPHITHEATRE PARKWAY

    (Street)
    MOUNTAIN VIEW CALIFORNIA 94043

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    1. Name and Address of Reporting Person*
    Alphabet Inc.

    (Last)(First)(Middle)
    1600 AMPHITHEATRE PARKWAY

    (Street)
    MOUNTAIN VIEW CALIFORNIA 94043

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    Explanation of Responses:
    1. The reported transaction represents a pro rata in-kind distribution, for no consideration, by the GV 2019, L.P. ("2019 Partnership") to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings LLC ("Alphabet Holdings"). The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
    2. The securities reported in this row are directly beneficially owned by the 2019 Partnership. GV 2019 GP, L.P. (the "2019 GP") is the general partner of the 2019 Partnership. GV 2019 GP, L.L.C. ("GV 2019 LLC") is the general partner of the 2019 GP. Alphabet Holdings is the sole member of GV 2019 LLC. XXVI Holdings Inc. ("XXVI") is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Exchange Act) the securities directly beneficially owned by the 2019 Partnership. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
    3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.81 to $23.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 5 and 6 of this Form 4.
    4. The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Exchange Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
    5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.83 to $23.81 per share, inclusive.
    6. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.835 to $24.74 per share, inclusive.
    7. The securities reported in this row are directly beneficially owned by GV 2021, L.P. (the "2021 Partnership"). GV 2021 GP, L.P. (the "2021 GP") is the general partner of the 2021 Partnership. GV 2021 GP, L.L.C. ("GV 2021 LLC") is the general partner of the 2021 GP. Alphabet Holdings is the sole member of GV 2021 LLC. XXVI is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2021 GP, GV 2021 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Exchange Act) the securities directly beneficially owned by the 2021 Partnership. Each of the 2021 GP, GV 2021 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
    /s/ Kim Burr, Authorized Signatory of GV 2019 GP, L.L.C.05/18/2026
    /s/ Kim Burr, Authorized Signatory of GV 2019 GP, L.P.05/18/2026
    /s/ Kim Burr, Authorized Signatory of GV 2019, L.P.05/18/2026
    /s/ Kim Burr, Authorized Signatory of GV 2021 GP, L.L.C.05/18/2026
    /s/ Kim Burr, Authorized Signatory of GV 2021 GP, L.P.05/18/2026
    /s/ Kim Burr, Authorized Signatory of GV 2021, L.P.05/18/2026
    /s/ Kathryn W. Hall, Assistant Secretary of Alphabet Inc.05/18/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $LIFE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LIFE

    DatePrice TargetRatingAnalyst
    2/23/2026$33.00Buy
    Goldman
    2/23/2026$18.00Outperform
    Robert W. Baird
    2/23/2026$21.00Mkt Outperform
    Citizens
    2/23/2026$20.00Overweight
    Barclays
    2/23/2026$23.00Buy
    Deutsche Bank
    2/23/2026$13.00Overweight
    Analyst
    2/23/2026$15.00Buy
    Citigroup
    2/23/2026Outperform
    William Blair
    More analyst ratings

    $LIFE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Botha Roelof bought $4,949,975 worth of shares (260,525 units at $19.00), converted options into 12,000,124 shares and returned 12,000,124 shares to the company (SEC Form 4)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    2/2/26 6:36:37 PM ET
    $LIFE
    Specialty Insurers
    Finance

    Director Wheeler William J bought $4,949,975 worth of shares (260,525 units at $19.00), increasing direct ownership by 2,481% to 271,025 units (SEC Form 4)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    1/30/26 8:49:26 PM ET
    $LIFE
    Specialty Insurers
    Finance

    Director Mullin Mark W. bought $99,997 worth of shares (5,263 units at $19.00), increasing direct ownership by 43% to 17,451 units (SEC Form 4)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    1/30/26 8:48:09 PM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Ethos Technologies Inc.

    SCHEDULE 13G - Ethos Technologies Inc. (0001788451) (Subject)

    5/15/26 9:00:02 PM ET
    $LIFE
    Specialty Insurers
    Finance

    SEC Form 144 filed by Ethos Technologies Inc.

    144 - Ethos Technologies Inc. (0001788451) (Subject)

    5/15/26 6:00:42 PM ET
    $LIFE
    Specialty Insurers
    Finance

    SEC Form 144 filed by Ethos Technologies Inc.

    144 - Ethos Technologies Inc. (0001788451) (Subject)

    5/15/26 5:59:47 PM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ethos Partners with Baseball Legend David Ortiz to Champion Life Insurance as a Family Financial Essential

    AUSTIN, Texas, May 21, 2026 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced a new partnership with baseball icon and 3x world champion David Ortiz. In a new campaign, Ortiz will share his profoundly personal story to help raise awareness about why life insurance can be an essential part of every family's financial protection plan—and how Ethos makes getting that coverage simple, fast, and accessible. "I've lost people I love more than anything, and I've almost lost my own life," said David Ortiz. "When you go through something like that, you stop thinking about tomorrow and start thinking about th

    5/21/26 9:07:00 AM ET
    $LIFE
    Specialty Insurers
    Finance

    Ethos to Present at Upcoming Investor Conferences

    AUSTIN, Texas, May 15, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ:LIFE), a leading life insurance technology company democratizing access to life insurance, today announced that Peter Colis, Co-founder and Chief Executive Officer, will present at the following investor conferences. Event Details: Bank of America Global Technology Conference on June 2, 2026 at 2:00 p.m. PT / 5:00 p.m. ETBaird 2026 Global Consumer, Technology & Services Conference on June 3, 2026 at 11:00 a.m. PT / 2:00 p.m. ETWilliam Blair 46th Annual Growth Stock Conference on June 4, 2026 at 7:20 a.m. PT / 10:20 a.m. ET A live webcast of the presentations will be available on Ethos's investor relations website at investor

    5/15/26 4:30:00 PM ET
    $LIFE
    Specialty Insurers
    Finance

    Ethos Announces Early Lock-Up Release

    Ethos (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced the applicable price condition for a partial early lock-up release pursuant to the terms of the lock-up agreements entered into in connection with Ethos's initial public offering has been satisfied. As a result, 25% of the eligible securities held by eligible holders as of February 15, 2026 ("Eligible Securities") will be automatically released from the lock-up restrictions immediately prior to opening of trading on May 14, 2026 and may be sold into the public market. The lock-up restrictions will continue to apply to all remaining shares subject to lock-u

    5/13/26 4:35:00 PM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Wang Lingke sold $1,024,561 worth of shares (46,349 units at $22.11), decreasing direct ownership by 14% to 695,302 units (SEC Form 4) (withholding tax)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    5/19/26 8:34:42 PM ET
    $LIFE
    Specialty Insurers
    Finance

    CEO and Secretary Colis Peter George sold $1,324,783 worth of shares (60,035 units at $22.07), decreasing direct ownership by 14% to 695,302 units (SEC Form 4) to satisfy withholding obligation

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    5/19/26 8:32:49 PM ET
    $LIFE
    Specialty Insurers
    Finance

    Chief Financial Officer Capozzi Christopher M. was granted 80,287 shares and sold $1,783,698 worth of shares (80,586 units at $22.13), decreasing direct ownership by 0.04% to 665,228 units (SEC Form 4) (tax liability)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    5/19/26 8:31:21 PM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Ethos Technologies with a new price target

    Goldman initiated coverage of Ethos Technologies with a rating of Buy and set a new price target of $33.00

    2/23/26 8:37:19 AM ET
    $LIFE
    Specialty Insurers
    Finance

    Robert W. Baird initiated coverage on Ethos Technologies with a new price target

    Robert W. Baird initiated coverage of Ethos Technologies with a rating of Outperform and set a new price target of $18.00

    2/23/26 8:37:19 AM ET
    $LIFE
    Specialty Insurers
    Finance

    Citizens initiated coverage on Ethos Technologies with a new price target

    Citizens initiated coverage of Ethos Technologies with a rating of Mkt Outperform and set a new price target of $21.00

    2/23/26 8:36:59 AM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Insurtech Leader Ethos Adds Industry Veteran William Wheeler to Board of Directors

    AUSTIN, Texas, July 30, 2025 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced the appointment of William J. Wheeler to its Board of Directors. Mr. Wheeler, a seasoned executive with deep expertise across insurance, retirement services, and investment banking, joins Ethos' distinguished board, further strengthening Ethos' governance and strategic guidance as the company continues its rapid growth and innovation. Mr. Wheeler brings more than three decades of leadership experience in the financial services industry. He most recently served as Vice Chairman of Athene Holding Ltd. (NYSE:ATH), a leadin

    7/30/25 11:00:00 AM ET
    $EVR
    $LIFE
    $ATH
    Investment Managers
    Finance
    Specialty Insurers
    Life Insurance

    aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor

    SAN DIEGO, Jan. 18, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) (aTyr or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Wayne A. I. Frederick, M.D., as an advisor to the company. Dr. Frederick is President Emeritus of Howard University, having served as President from 2014 to 2023. "We are honored to welcome a distinguished physician executive such as Dr. Frederick as an advisor to aTyr," said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. "Dr. Frederick's clinical background combined with

    1/18/24 8:00:00 AM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

    SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

    2/14/24 1:43:55 PM ET
    $LIFE
    Specialty Insurers
    Finance

    SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

    SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

    2/13/24 4:30:17 PM ET
    $LIFE
    Specialty Insurers
    Finance

    SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

    SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

    2/9/24 8:35:54 AM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Financials

    Live finance-specific insights

    View All

    Ethos to Announce First Quarter 2026 Financial Results on May 6, 2026

    AUSTIN, Texas, April 02, 2026 (GLOBE NEWSWIRE) -- Ethos Technologies Inc. (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced that it will release its financial results for the first quarter of 2026, which ended March 31, 2026, following the close of U.S. financial markets on Wednesday, May 6, 2026. The company's earnings press release will be made available on the Ethos Investor Relations website at investors.ethos.com. Ethos executives will host a conference call to discuss the results at 1:30 p.m. PT / 4:30 p.m. ET the same day. The live webcast of the conference call can be found on the Ethos Investor Relatio

    4/2/26 4:05:00 PM ET
    $LIFE
    Specialty Insurers
    Finance

    Ethos Reports Fourth Quarter and Fiscal Year 2025 Financial Results

    Records full-year revenue of $387.6 million, growing 52% year-over-yearAchieves Net Income of $24.6 million and Adjusted EBITDA of $25.8 million in Q4, reflecting a 22% margin and a 23% Adjusted EBITDA marginDelivers third consecutive year of revenue growth greater than 50% AUSTIN, Texas, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. "We delivered a strong close to 2025 with 65% year-over-year revenue growth in Q4," said Peter Colis, CEO and Co-Founder of Ethos. "Our financial resul

    2/25/26 4:05:00 PM ET
    $LIFE
    Specialty Insurers
    Finance

    aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

    Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024. Company launches Individual Patient Expanded Access Program (EAP), allowing access to efzofitimod for patients who complete EFZO-FIT™. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD currently enrolling. Ended 2023 with $101.7 million in cash, cash equivalents and investments. Company to host conference call and webcast today, March 14th, at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, March 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged

    3/14/24 4:00:00 PM ET
    $LIFE
    Specialty Insurers
    Finance